 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq...

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD...

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Laidlaw assumed coverage on shares of Silo Pharma (NASDAQ:SILO  Free Report) in a research report sent to investors on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a...

Silo Pharma (NASDAQ:SILO) Receives New Coverage from Analysts at Laidlaw

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Silo Pharma initiated with a Buy at Laidlaw

Clarivate will monitor, manage, and maintain Companys expanding IP portfolio ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.(Nasdaq: SILO) (the Company), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, ...

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Study data to determine potential delivery partners ENGLEWOOD CLIFFS, NJ, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.(Nasdaq: SILO) (the Company), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it ...

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders

Silo Pharma shares take off as anxiety and PTSD therapeutic candidate achieves milestone

Silo Pharma (NASDAQ:SILO  Get Free Report) and Lanvin Group (NYSE:LANV  Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, ...

Financial Contrast: Silo Pharma (NASDAQ:SILO) and Lanvin Group (NYSE:LANV)

Silo Pharma (NASDAQ:SILO Get Free Report) and Lanvin Group (NYSE:LANV Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, ...

Contrasting Silo Pharma (NASDAQ:SILO) & Lanvin Group (NYSE:LANV)

Silo Pharma (NASDAQ:SILO Free Report) and Lanvin Group (NYSE:LANV Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, ...

Silo Pharma (NASDAQ:SILO) and Lanvin Group (NYSE:LANV) Head to Head Contrast

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Englewood Cliffs, NJ.

Watchers	1,066
52-Wk Low	$1.71
52-Wk High	$7.26

Market Cap	$5.6M
Volume (M)	38,620.00
52-Wk High	$7.26
52-Wk Low	$1.71

SILO Silo Pharma Inc

About

Feed

News

Fundamentals